HPM Web Site

  • HPM Web Site

Get Updates via E-mail

  • Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.

    Delivered by FeedBurner

 Subscribe in a reader




Disclaimer

  • FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.

    Copyright 2011 Hyman, Phelps & McNamara, P.C.

Awards & Honors












« ViroPharma Sues FDA Over March 2006 Bioequivalence Determination; FOIA Lawsuit a Possible Precursor to Future Litigation | Main | Two Upcoming Conferences Discuss Product Lifecycle Management Issues »

December 23, 2008

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d150c53ef010536956a42970c

Listed below are links to weblogs that reference AdvaMed Releases Revised "Code on Ethics on Interactions with Health Care Professionals" that is More Restrictive than Prior Version and Mirrors Revised PhRMA Code in Many Respects; HPM Issues Summary Memorandum :

Comments

The comments to this entry are closed.

180-Day Exclusivity Tracker

Citizen Petition Tracker

REMS Tracker

Legislation Tracker